generation run 2026-05-11
82 min completedmodel pipeline-v5plan not recordedrun/9b13f346…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
6 further caveats recorded as free text — readable on the working page
Reproduce
- inputs
- 46 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
18 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | Web | cannabichromene CBC CAS number SMILES physical properties melting point | 10 | 0 | — |
| 2 | Web | cannabichromene CBC discovery 1966 Gaoni Mechoulam first isolated | 10 | 0 | — |
| 3 | PubMed | cannabichromene anticancer antitumor | 7 | 4 | — |
| 4 | PubMed | cannabichromene pharmacology receptor binding | 12 | 7 | — |
| 5 | PubMed | cannabichromene intestinal motility 5-HT3 | 1 | 1 | — |
| 6 | PubMed | cannabichromene biosynthesis CBCA synthase | 8 | 4 | — |
| 7 | Crossref (verify_doi) | 10.1039/c19660000020 | 1 | 1 | — |
| 8 | Web | cannabichromene CBC legal status United States DEA scheduling 2026 | 10 | 0 | — |
| 9 | OpenAlex | cannabichromene CBC pharmacology | 10 | 4 | — |
| 10 | PubMed | PMID 7298870 | 1 | 1 | — |
| 11 | PubMed | cannabichromene antimicrobial antibacterial Staphylococcus MRSA | 8 | 5 | — |
| 12 | OpenAlex | cannabichromene CBC discovery isolation cannabis | 10 | 0 | — |
| 13 | Web | cannabichromene CBC legal status UK EU Canada Australia 2025 | 10 | 0 | — |
| 14 | PubMed | cannabichromene anti-inflammatory analgesic pain | 6 | 4 | — |
| 15 | PubMed | cannabichromene TRPA1 TRPV1 TRP channels | 3 | 3 | — |
| 16 | PubChem | cannabichromene | 1 | 1 | — |
| 17 | ClinicalTrials.gov | cannabichromene CBC | 4 | 1 | — |
| 18 | PubMed | cannabichromene CYP450 cytochrome metabolism hepatic | 3 | 2 | — |
76 claims by section — every cited sentence, checked against its source
safety20 · 17 ok
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — not_supportednot supportedworking →
CBC inhibited FSH-stimulated granulosa cell function in vitro — a direct antigonadal effect shared as a class property with both psychoactive and non-psychoactive cannabinoidssupported
CBC (like other cannabinoids including THC, CBD, CBN, CBG) inhibited FSH-stimulated progesterone and estrogen biosynthesis in rat granulosa cells. Direct antigonadal activity observed at pharmacologically relevant concentrations. ajpendo.1983.245.1.e4
Historical data demonstrated CBC inhibition of lymphocyte PHA response at concentrations of 10⁻⁵–10⁻⁴ Msupported
CBC at 10-5 to 10-4 M concentrations inhibited lymphocyte PHA response and macromolecular synthesis. fpsyt.2011.00012
CBC potentiates barbiturate- and CNS depressant-induced hypnosis in micesupported
Previously reported CBC potentiation of CNS depressant-induced hypnosis is not mediated by the hepatic microsomal enzyme system. 0306-3623(83)90007-3
It does not generate THC-like discriminative stimulus in trained rats at doses up to 30 mg/kg and does not produce cannabimimetic effects in mouse drug discrimination assayspartially supported
CBC and other minor cannabinoids had little effect on THC discriminative stimulus in rats. can.2023.0062
It does not generate THC-like discriminative stimulus in trained rats at doses up to 30 mg/kg and does not produce cannabimimetic effects in mouse drug discrimination assayspartially supported
Minor cannabinoids evaluated for THC-like psychoactivity in mouse THC drug discrimination and CB1/CB2 binding affinities. j.pnpbp.2024.110984
CBC did not produce cannabimimetic effects in drug discrimination models and did not alter the interoceptive effects of THC in trained rats, suggesting minimal abuse potential through the endocannabinoid systempartially supported
Minor cannabinoids evaluated for THC-like psychoactivity in mouse THC drug discrimination and CB1/CB2 binding affinities. j.pnpbp.2024.110984
CBC did not produce cannabimimetic effects in drug discrimination models and did not alter the interoceptive effects of THC in trained rats, suggesting minimal abuse potential through the endocannabinoid systemsupported
CBC and other minor cannabinoids had little effect on THC discriminative stimulus in rats. None lowered THC responding to 50% or below. can.2023.0062
CBC is metabolized by CYPs 1A2, 2B6, 2C8, 2C19, 2D6, and 3A4supported
CYPs 1A2, 2B6, 2C8, 2C19, 2D6 and 3A4 involved in CBC hydroxylation. j.taap.2023.116654
However, because CBC does not significantly inhibit hepatic microsomal enzymes, it is less likely than CBD to cause clinically significant elevation of co-administered drug levels.supported
CBC pretreatment had no effect on in vitro hepatic microsomal enzyme activity. 0306-3623(83)90007-3
CBC + CBD co-administration in rats increased mutual C_max and AUC without altering T_max, consistent with competitive substrate interaction at shared CYP isoformspartially supported
Co-administration increased Cmax and AUC. s13346-026-02057-1
CBC potentiated pentobarbital/CNS depressant-induced hypnosis in mice through a non-CYP-mediated mechanismsupported
Previously reported CBC potentiation of CNS depressant-induced hypnosis is not mediated by the hepatic microsomal enzyme system. 0306-3623(83)90007-3
CBC synergized with β-caryophyllene (a CB2 agonist terpene present in cannabis, black pepper, and many consumer products) in cancer cell modelssupported
CBC greatest potency among tested cannabinoids; synergistically reduced IC50 with beta-caryophyllene in TNBC. ijms27062730
In the colitis model, CBC achieved therapeutic effects at subtherapeutic doses only in combination with CBD, CBDV, and CBGsupported
CBC combination with CBD, CBDV, CBG at subtherapeutic doses reduced visceral hypersensitivity. jpet.2025.103389
Claim in safety — inconclusiveinconclusiveworking →
Relative (inferred): * Concurrent CNS depressant use: CBC's pharmacodynamic potentiation of CNS depressants in animal models and its GABA_A PAM activity suggest additive sedation risk with benzodiazepines, barbiturates, opioids, and alcohol. * Drugs metabolized by CYP1A2, CYP2C19, CYP2D6, or CYP3A4: Although CBC does not significantly inhibit these enzymes, competitive substrate interactions may alter PK of both CBC and co-administered drugs. * Pregnancy and lactation: In vitro antigonadal effects observed across the cannabinoid classsupported
Previously reported CBC potentiation of CNS depressant-induced hypnosis is not mediated by the hepatic microsomal enzyme system. 0306-3623(83)90007-3
Relative (inferred): * Concurrent CNS depressant use: CBC's pharmacodynamic potentiation of CNS depressants in animal models and its GABA_A PAM activity suggest additive sedation risk with benzodiazepines, barbiturates, opioids, and alcohol. * Drugs metabolized by CYP1A2, CYP2C19, CYP2D6, or CYP3A4: Although CBC does not significantly inhibit these enzymes, competitive substrate interactions may alter PK of both CBC and co-administered drugs. * Pregnancy and lactation: In vitro antigonadal effects observed across the cannabinoid classsupported
CBC enhanced GABA-induced currents in Xenopus oocytes and mouse primary cortical neurons. V436 in beta2 subunit of GABAA receptor identified as critical binding site for CBC. j.fmre.2023.05.023
Relative (inferred): * Concurrent CNS depressant use: CBC's pharmacodynamic potentiation of CNS depressants in animal models and its GABA_A PAM activity suggest additive sedation risk with benzodiazepines, barbiturates, opioids, and alcohol. * Drugs metabolized by CYP1A2, CYP2C19, CYP2D6, or CYP3A4: Although CBC does not significantly inhibit these enzymes, competitive substrate interactions may alter PK of both CBC and co-administered drugs. * Pregnancy and lactation: In vitro antigonadal effects observed across the cannabinoid classsupported
CYPs 1A2, 2B6, 2C8, 2C19, 2D6 and 3A4 involved in CBC hydroxylation. j.taap.2023.116654
Relative (inferred): * Concurrent CNS depressant use: CBC's pharmacodynamic potentiation of CNS depressants in animal models and its GABA_A PAM activity suggest additive sedation risk with benzodiazepines, barbiturates, opioids, and alcohol. * Drugs metabolized by CYP1A2, CYP2C19, CYP2D6, or CYP3A4: Although CBC does not significantly inhibit these enzymes, competitive substrate interactions may alter PK of both CBC and co-administered drugs. * Pregnancy and lactation: In vitro antigonadal effects observed across the cannabinoid classsupported
CBC (like other cannabinoids including THC, CBD, CBN, CBG) inhibited FSH-stimulated progesterone and estrogen biosynthesis in rat granulosa cells. Direct antigonadal activity observed at pharmacologically relevant concentrations. ajpendo.1983.245.1.e4
pharmacology13 · 13 ok
The seed database classification of CBC as a "CB1 receptor partial agonist" is contradicted by published data and requires correction.supported
CBC exhibited 10-100x lower CB1/CB2 affinity than THC. bs.pbr.2025.07.006
The seed database classification of CBC as a "CB1 receptor partial agonist" is contradicted by published data and requires correction.supported
Ki values to CB1 range from 23.5 nM (THCA) to 14711 nM (CBDV). j.ntt.2014.09.003
De Petrocellis et al. established CBC as one of the most potent phytocannabinoid agonists of rat TRPA1 channels, ranking alongside CBD and CBNsupported
CBC, CBD and CBN were potent rat TRPA1 agonists. j.1476-5381.2010.01166.x
This mechanism underlies CBC's analgesic and anti-inflammatory effects and mediates its inhibition of intestinal hypermotility.supported
CBC is a major non-psychotropic phytocannabinoid that inhibits endocannabinoid inactivation and activates TRPA1. CBC inhibited inflammation-induced intestinal hypermotility in mice. j.1476-5381.2012.01879.x
Wang et al. demonstrated that CBC enhances GABA-induced currents in both Xenopus laevis oocytes and mouse primary cortical neuronssupported
CBC enhanced GABA-induced currents in Xenopus oocytes and mouse primary cortical neurons. j.fmre.2023.05.023
This mechanism accounts for CBC's anti-seizure effects, confirmed independently by Jin and Huang.supported
CBC showed strong allosteric enhancement effects on CBD binding site of GABAA receptor. j.fmre.2024.11.002
CBC additionally modulates endocannabinoid tone through two mechanisms: inhibition of N-acylethanolamine acid amide hydrolase (NAAA), the enzyme responsible for degrading palmitoylethanolamide (PEA), and blockade of anandamide cellular uptake (ACU), with potency matching CBG and exceeding CBDsupported
CBC inhibited NAAA. CBC = CBG > CBD inhibited anandamide cellular uptake. j.1476-5381.2010.01166.x
In vivo antidepressant studies in mice report CBC inhibited monoamine oxidase A (MAO-A) activity in brain tissue at 20 mg/kg, contributing to elevated monoamine levels — a proposed mechanism for antidepressant-like behavioral effects comparable to imipramine at 15 mg/kg.partially supported
CBC at 20 mg/kg reduced immobility in stressed mice, similar to imipramine. Reduced corticosterone and MAO-A activity. s00210-025-04236-2
In cannulated rats, Rysanek et al. demonstrated that intestinal lymphatic transport plays a major role in CBC absorption following oral administrationsupported
Intestinal lymphatic transport plays major role in CBC absorption. acs.molpharmaceut.4c01357
Co-administration of CBC (10 mg/kg i.p.) with CBD (20 mg/kg i.p.) in rats increased the C_max and AUC of both compounds without altering T_maxpartially supported
Co-administration increased Cmax and AUC. s13346-026-02057-1
The major Phase I metabolite of CBC, identified following incubation with human liver microsomes, is 2'-hydroxycannabicitran — a novel oxidized structure characterized by GC-MS and NMR spectroscopy. In silico modeling predicted this metabolite would fit the orthosteric binding site of both CB1 and CB2 receptors, but in vitro competitive binding assays showed no significant activity at either receptor.supported
CBC major Phase I metabolite identified as 2-hydroxycannabicitran via GC-MS and NMR. In silico modeling predicted metabolite fits in orthosteric site of CB1 and CB2 but showed no significant binding. metabo14060329
Recombinant human CYP screening established that CBC is hydroxylated predominantly by CYPs 1A2, 2B6, 2C8, 2C19, 2D6, and 3A4supported
CYPs 1A2, 2B6, 2C8, 2C19, 2D6 and 3A4 involved in CBC hydroxylation. j.taap.2023.116654
Kapeghian et al. demonstrated in mouse liver preparations that CBC pretreatment did not alter microsomal enzyme function, suggesting CBC is metabolized by but does not inhibit these enzymes at pharmacologically relevant concentrations.supported
CBC pretreatment had no effect on in vitro hepatic microsomal enzyme activity. 0306-3623(83)90007-3
clinical-evidence10 · 10 ok
CBC at 20 mg/kg reduced immobility in forced swim and tail suspension tests in chronic unpredictable mild stress (CUMS) mice, with efficacy comparable to imipramine at 15 mg/kgpartially supported
CBC at 20 mg/kg reduced immobility in stressed mice, similar to imipramine. s00210-025-04236-2
Turner and ElSohly demonstrated anti-inflammatory activity superior to phenylbutazone in the foundational 1981 studysupported
CBC was superior to phenylbutazone in anti-inflammatory activity (carrageenan rat paw edema and erythrocyte membrane stabilization). j.1552-4604.1981.tb02555.x
In human keratinocytes, CBC exerted anti-inflammatory effects via endocannabinoid system modulation and MAPK signalingsupported
CBC blocked inflammation by reducing pro-inflammatory interleukins in LPS-stimulated human keratinocytes via ECS and MAPK signaling. ijms24032721
Maione et al. demonstrated that CBC modulates the descending antinociceptive pathway in anesthetized rats through multiple mechanisms of actionsupported
CBD and CBC modulate TRP channels involved in nociception and the descending pain pathway in anaesthetized rats. j.1476-5381.2010.01063.x
Wang et al. demonstrated reduced seizure susceptibility and prolonged seizure latency in drug-induced seizure models, mechanistically linked to GABA_A positive allosteric modulationsupported
CBC enhanced GABA-induced currents in Xenopus oocytes and mouse primary cortical neurons. V436 in beta2 subunit of GABAA receptor identified as critical binding site for CBC. j.fmre.2023.05.023
CBC demonstrates potent antibacterial activity against MRSA and other Gram-positive organismssupported
All five major cannabinoids including CBC showed potent activity against MRSA strains. np8002673
Anti-biofilm activity against MRSA has been demonstrated, and synergistic bactericidal activity with silver nanoparticles against healthcare-associated pathogens has been reportedpartially supported
Systematically evaluated antimicrobial amplification properties of cannabinoids including CBC to increase antimicrobial effect of silver against Gram-positive and Gram-negative HAI pathogens. lxag092
CBC exhibits cytotoxicity against multiple cancer cell lines in vitro: triple-negative breast cancer (synergy with β-caryophyllene), drug-resistant breast cancer (synergy with CBD), multiple myeloma, glioblastoma (with GPR55 involvement proposed), ER-positive breast cancer, and colon cancersupported
CBC greatest potency among tested cannabinoids; synergistically reduced IC50 with beta-caryophyllene in TNBC. ijms27062730
CBC exhibits cytotoxicity against multiple cancer cell lines in vitro: triple-negative breast cancer (synergy with β-caryophyllene), drug-resistant breast cancer (synergy with CBD), multiple myeloma, glioblastoma (with GPR55 involvement proposed), ER-positive breast cancer, and colon cancersupported
CBC inhibited MM cell growth and induced necrotic cell death; reduced invasion and bone resorption. biof.2078
CBC exhibits cytotoxicity against multiple cancer cell lines in vitro: triple-negative breast cancer (synergy with β-caryophyllene), drug-resistant breast cancer (synergy with CBD), multiple myeloma, glioblastoma (with GPR55 involvement proposed), ER-positive breast cancer, and colon cancersupported
Synthetically obtained CBC induced apoptosis in colon cancer cells by modulating mitochondrial dehydrogenase activity and membrane integrity. cells13191616
summary8 · 7 ok
Unlike Δ⁹-THC, CBC exhibits negligible affinity for CB1 receptors (10–100× lower binding than THC) and does not produce intoxication or cannabimimetic discriminative stimulus in animal modelspartially supported
CBC exhibited 10-100x lower CB1/CB2 affinity than THC. bs.pbr.2025.07.006
Unlike Δ⁹-THC, CBC exhibits negligible affinity for CB1 receptors (10–100× lower binding than THC) and does not produce intoxication or cannabimimetic discriminative stimulus in animal modelssupported
Minor cannabinoids evaluated for THC-like psychoactivity in mouse THC drug discrimination and CB1/CB2 binding affinities. j.pnpbp.2024.110984
Claim in summary — inconclusiveinconclusiveworking →
Early characterization identified CBC as the second most abundant cannabinoid in drug-type cannabis, with anti-inflammatory potency exceeding the NSAID phenylbutazonesupported
CBC is the second most abundant cannabinoid in drug-type cannabis. CBC was superior to phenylbutazone in anti-inflammatory activity. j.1552-4604.1981.tb02555.x
CBC acts primarily through potent TRPA1 agonism followed by receptor desensitization, producing analgesia via nociceptor silencingpartially supported
CBC, CBD and CBN were potent rat TRPA1 agonists. j.1476-5381.2010.01166.x
A second major mechanism — positive allosteric modulation of GABA_A receptors at the β2 subunit valine-436 residue — underlies its anti-seizure effectssupported
V436 in beta2 subunit of GABAA receptor identified as critical binding site for CBC. j.fmre.2023.05.023
Additional activity includes inhibition of N-acylethanolamine acid amide hydrolase (NAAA) and blockade of anandamide cellular uptake, both elevating local endocannabinoid tone.supported
CBC inhibited NAAA. CBC = CBG > CBD inhibited anandamide cellular uptake. j.1476-5381.2010.01166.x
Animal data indicate CBC potentiates CNS depressant-induced sedation through a pharmacodynamic (not pharmacokinetic) mechanism, warranting caution with co-administered sedativessupported
Previously reported CBC potentiation of CNS depressant-induced hypnosis is not mediated by the hepatic microsomal enzyme system. 0306-3623(83)90007-3
comparative-pharmacology6 · 6 ok
CBC shows 10–100× lower binding at both receptors and does not produce cannabimimetic discriminative stimulus at doses up to 30 mg/kg in ratspartially supported
CBC exhibited 10-100x lower CB1/CB2 affinity than THC. bs.pbr.2025.07.006
CBC shows 10–100× lower binding at both receptors and does not produce cannabimimetic discriminative stimulus at doses up to 30 mg/kg in ratspartially supported
CBC and other minor cannabinoids had little effect on THC discriminative stimulus in rats. can.2023.0062
CBC acts primarily at TRPA1 and GABA_A (β2 subunit) with NAAA inhibition.partially supported
CBC, CBD and CBN were potent rat TRPA1 agonists. CBC inhibited NAAA. j.1476-5381.2010.01166.x
A critical distinction: CBD is a significant CYP inhibitor (clinically relevant interactions with clobazam, warfarin, and others have been documented in humans), while CBC does not appear to inhibit CYP enzymessupported
CBD+THC brownie inhibited CYP2C19 > CYP2C9 > CYP3A > CYP1A2 in 18 healthy adults. cpt.2973
CBC showed higher susceptibility to CYP-mediated transformation than CBD in recombinant enzyme screening, potentially resulting in faster hepatic clearance.supported
CBC showed higher susceptibility to CYP-mediated transformation than other tested cannabinoids. j.taap.2023.116654
In the colitis-visceral pain model, CBC was effective only at subtherapeutic doses when combined with CBD, CBDV, and CBG, a finding consistent with the entourage effect hypothesis elaborated by Russosupported
CBC combination with CBD, CBDV, CBG at subtherapeutic doses reduced visceral hypersensitivity. jpet.2025.103389
neuroscience5 · 5 ok
Monoaminergic effects: MAO-A inhibition in mouse brain tissue at 20 mg/kg would be expected to increase synaptic concentrations of serotonin, norepinephrine, and dopamine — consistent with the antidepressant-like behavioral phenotype observed in the CUMS model.supported
CBC at 20 mg/kg reduced immobility in stressed mice, similar to imipramine. Reduced corticosterone and MAO-A activity. s00210-025-04236-2
TRPA1-mediated nociceptive modulation: CBC's potent TRPA1 agonism affects nociceptive processing through the descending antinociceptive pathwaypartially supported
CBC, CBD and CBN were potent rat TRPA1 agonists. j.1476-5381.2010.01166.x
GABAergic enhancement: CBC's positive allosteric modulation at GABA_A β2 subunits (V436) potentiates inhibitory neurotransmissionsupported
CBC enhanced GABA-induced currents in Xenopus oocytes and mouse primary cortical neurons. V436 in beta2 subunit of GABAA receptor identified as critical binding site for CBC. j.fmre.2023.05.023
Neurogenesis: Zagožen et al. cite a potential in vitro effect of CBC on adult neural stem progenitor cells, but the primary source for this claim was not retrievable in the current researchsupported
CBC shows anti-inflammatory effects, reduces gut hypermotility, has potential effect on adult neural stem progenitor cells. acph-2021-0021
CBC's subtherapeutic-dose efficacy in combination with other cannabinoids and its synergy with β-caryophyllene provide direct experimental support for this hypothesis.supported
CBC combination with CBD, CBDV, CBG at subtherapeutic doses reduced visceral hypersensitivity. jpet.2025.103389
history4 · 3 ok
Claim in history — inconclusiveinconclusiveworking →
CBCA synthase — the FAD-dependent oxidoreductase that cyclizes cannabigerolic acid (CBGA) into cannabichromenic acid (CBCA) — was identified and purified by Taura, Sirikantaramas, Shoyama, and colleagues in the early 2000ssupported
CBCA synthase purified from Cannabis sativa. Biosynthetic pathways for THC, CBD and CBC established. 138920107781996823
Notably, CBCA is the first cannabinoid to accumulate in Cannabis seedlings after germination, suggesting a possible developmental or protective role in early plant growth.supported
Cannabichromenic acid is the first cannabinoid accumulating in Cannabis seedlings after emergence. j.phytochem.2023.113793
Under acidic conditions, CBC undergoes photoisomerization to cannabicyclol (CBL), as demonstrated by Haghdoost et al. using Montmorillonite K30 clay in chloroform at room temperature (60% conversion yield)partially supported
CBC converts to cannabicyclol (CBL) under acidic conditions. acs.jnatprod.4c00977
receptor-pharmacology4 · 3 ok
CBC exhibits 10–100× lower binding affinity for both CB1 and CB2 receptors compared to Δ⁹-THC, as established by a 2025 systematic review and meta-analysis of phytocannabinoid binding affinitiessupported
Systematic review/meta-analysis of phytocannabinoid binding affinities. CBC exhibited 10-100x lower CB1/CB2 affinity than THC. bs.pbr.2025.07.006
An in silico molecular docking study reported CBC docking scores of −9.4 at CB2 receptors, nominally superior to CBD (−8.8) and THC (−9.1)partially supported
CBC docking score -9.4 to CB2. s00210-025-04236-2
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
In silico docking studies report CBC binding to GPR55, a putative non-canonical cannabinoid receptor implicated in CBC's anti-glioma cytotoxicitysupported
CBC exhibited strong binding affinities for GPR55 and PINK1 in glioblastoma. ijms26125688
chemistry3 · 2 ok
Claim in chemistry — inconclusiveinconclusiveworking →
Calcaterra et al. demonstrated that the enantiomeric composition is genetically determined, linked to differential expression of CBCA synthase isoforms and associated proteins with antipodal enantiospecificitysupported
CBC occurs in Cannabis as a scalemate with strain-dependent enantiomeric composition. Genetic basis linked to CBCA-synthase isoforms. acs.jnatprod.2c01139
CBCA is the first cannabinoid to accumulate in cannabis seedlings after germination, preceding both THCA and CBDAsupported
Cannabichromenic acid is the first cannabinoid accumulating in Cannabis seedlings after emergence. j.phytochem.2023.113793
pharmacokinetic-detail3 · 3 ok
Co-administration of CBC (10 mg/kg i.p.) with CBD (20 mg/kg i.p.) in rats produced mutual increases in C_max and AUC without altering T_max, consistent with competitive substrate interaction at shared CYP isoforms (likely CYP2C8 and CYP2C19)partially supported
Co-administration increased Cmax and AUC. s13346-026-02057-1
Rysanek et al. conducted pharmacokinetic studies in jugular vein cannulated and mesenteric lymph duct cannulated rats to characterize oral CBC absorptionsupported
Nanoemulsion led to 3-fold increase in absolute bioavailability of CBC via lymph and 8-fold increase via portal vein. Intestinal lymphatic transport plays major role in CBC absorption. acs.molpharmaceut.4c01357
Recombinant human CYP screening by Havlasek et al. identified six primary CYP isoforms responsible for CBC hydroxylation: CYP1A2, CYP2B6, CYP2C8, CYP2C19, CYP2D6, and CYP3A4supported
CYPs 1A2, 2B6, 2C8, 2C19, 2D6 and 3A4 involved in CBC hydroxylation. j.taap.2023.116654